D. Hollenbaugh

发表

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

P. Linsley, A. Aruffo, C. Larsen, 1996, Nature.

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

A. Thakur, D. Chao, E. DiGiammarino, 2020, Molecular Cancer Therapeutics.

The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity.

I. Stamenkovic, A. Aruffo, J. Ledbetter, 1992, The EMBO journal.

TransplantationGraft Survival in Murine Models of with CTLA4-Ig in Promoting Long-Term Anti-CD40 Monoclonal Antibody Synergizes

Z. Milas, C. Larsen, Shivaprakash Gangappa, 2009 .

Transplantation Graft Survival in Murine Models of with CTLA 4-Ig in Promoting Long-Term Anti-CD 40 Monoclonal Antibody

Z. Milas, C. Larsen, Shivaprakash Gangappa, 2009 .

Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation

Z. Milas, C. Larsen, Shivaprakash Gangappa, 2009, The Journal of Immunology.

Sulfated galactocerebrosides as potential antiinflammatory agents.

J. Bajorath, A. Aruffo, G. Todderud, 1997, Journal of medicinal chemistry.

The Human gp39 Promoter

D. Lewis, L. Schubert, A. Aruffo, 1995, The Journal of Biological Chemistry.

B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells

H. Ochs, A. Aruffo, J. Ledbetter, 1993, The Journal of experimental medicine.

Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease.

A. Aruffo, D. Hollenbaugh, 2001, Current opinion in immunology.

Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.

S. Kanner, H. Ochs, A. Aruffo, 1997, Blood.

T-cell activation molecule 4-1BB binds to extracellular matrix proteins.

R. Peach, A. Aruffo, J. Ledbetter, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Use of Monoclonal Antibodies for Expression Cloning

P. Linsley, A. Aruffo, D. Hollenbaugh, 1999, Current protocols in molecular biology.

Use of Monoclonal Antibodies for Expression Cloning

P. Linsley, A. Aruffo, D. Hollenbaugh, 1999, Current protocols in immunology.

Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes.

P. Kiener, A. Wahl, A. Aruffo, 1995, Journal of immunology.

The Role of CD40 and its Ligand in the Regulation of the Immune Response

H. Ochs, A. Aruffo, J. Ledbetter, 1994, Immunological reviews.

Vivo Alloantigen-Induced Hyporesponsiveness In The Role of the CD 40 Pathway in Fanslow

P. Linsley, R. Geha, A. Aruffo, 1998 .

CD40 ligand triggers interleukin-6 mediated B cell differentiation.

M. Urashima, A. Ogata, D. Chauhan, 1996, Leukemia research.

Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.

A. Gown, P. Linsley, M. Kay, 1997, Proceedings of the National Academy of Sciences of the United States of America.

CD40L is Critical for Protection from Demyelinating Disease and Development of Spontaneous Remyelination in a Mouse Model of Multiple Sclerosis

Moses Rodriguez, M. Rodriguez, D. Hollenbaugh, 2000, Brain pathology.

Cell-Dependent Antigens Factor in the Humoral Response to T Cutting Edge : CD 40 Ligand Is a Limiting

Christopher B Wilson, D. Hollenbaugh, M. Pérez-Melgosa, 1999 .

Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome.

H. Ochs, A. Aruffo, H. Pabst, 1998, Blood.

Expression of Functional CD 40 by Vascular Endothelial Cells

P. Kiener, A. Aruffo, R. Denfeld, 2003 .

The Wiskott-Aldrich syndrome protein

H. Ochs, A. Aruffo, R. Blaese, 1996 .

Cleavable CD40Ig fusion proteins and the binding to sgp39.

A. Aruffo, D. Hollenbaugh, V. McDonald, 1995, Journal of immunological methods.

The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1.

H. Ochs, A. Aruffo, J. Ledbetter, 1994, The Journal of clinical investigation.

Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series.

D. Cheney, Ping Chen, Derek J. Norris, 2003, Bioorganic & medicinal chemistry letters.

Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety.

D. Cheney, Ping Chen, Henry H. Gu, 2003, Bioorganic & medicinal chemistry letters.

CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.

H. Ochs, A. Aruffo, J. Ledbetter, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Mutations of the CD40 LigandGene and Its Effect on CD40 Ligand Expression in Patients With X-Linked Hyper IgM Syndrome

H. Ochs, A. Aruffo, H. Pabst, 1998 .

Mutations of the CD 40 Ligand Gene and Its Effect on CD 40 Ligand Expression in Patients With X-Linked Hyper IgM Syndrome

H. Ochs, A. Aruffo, H. Pabst, 1998 .

The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.

H. Ochs, A. Aruffo, D. Hollenbaugh, 1994, Seminars in immunology.

Transient Inhibition of CD28 and CD40 Ligand Interactions Prolongs Adenovirus-Mediated Transgene Expression in the Lung and Facilitates Expression after Secondary Vector Administration

P. Linsley, M. Kay, A. Aruffo, 1998, Journal of Virology.

Administration Expression after Secondary Vector Expression in the Lung and Facilitates Adenovirus-Mediated Transgene Ligand Interactions Prolongs Transient Inhibition of CD 28 and CD 40

P. Linsley, M. Kay, A. Aruffo, 1998 .

Anti-CD40 therapy extends renal allograft survival in rhesus macaques1

A. Aruffo, C. Larsen, D. Hollenbaugh, 2002, Transplantation.

Induction of costimulatory molecules B7-1 and B7-2 in murine B cells. the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction.

M. Debenedette, T. Watts, D. Hollenbaugh, 1996, Molecular immunology.

Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors.

D. Cheney, Ping Chen, Derek J. Norris, 2003, Bioorganic & medicinal chemistry letters.

Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3.

D. Cheney, E. Iwanowicz, J. Barrish, 2003, Bioorganic & medicinal chemistry letters.

Novel guanidine-based inhibitors of inosine monophosphate dehydrogenase.

Henry H. Gu, E. Iwanowicz, J. Barrish, 2002, Bioorganic & medicinal chemistry letters.

Novel amide-based inhibitors of inosine 5'-monophosphate dehydrogenase.

Henry H. Gu, E. Iwanowicz, J. Barrish, 2002, Bioorganic & medicinal chemistry letters.

Novel diamide-based inhibitors of IMPDH.

Henry H. Gu, E. Iwanowicz, M. Witmer, 2002, Bioorganic & medicinal chemistry letters.

Recombinant globulins: novel research tools and possible pharmaceuticals.

A. Aruffo, D. Hollenbaugh, N. J. Chalupny, 1992, Current opinion in immunology.

Central Nervous System Toxoplasmosis with an Increased Proportion of Circulating γδ T Cells in a Patient with Hyper-IgM Syndrome

D. Hollenbaugh, R. Sorensen, L. Leiva, 1998, Journal of Clinical Immunology.

Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.

H. Haugen, C. Clegg, A. Aruffo, 1997, International immunology.

Construction of Immunoglobulin Fusion Proteins

A. Aruffo, D. Hollenbaugh, 2002, Current protocols in immunology.

The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome

J. Bajorath, U. Francke, H. Ochs, 1993, Cell.

Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome

L. Williams, E. Bosch, J. Wong, 2008, Science.

Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

K. Baker, L. Williams, W. Kavanaugh, 2013, Science Translational Medicine.

A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity

D. Song, A. Wahl, D. Chao, 2019, Cancer Immunology Research.

CD40 is functionally expressed on human keratinocytes

Alejandro Aruffo, J. Simon, A. Aruffo, 1996, European journal of immunology.

Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens.

C. Wilson, D. Hollenbaugh, M. Pérez-Melgosa, 1999, Journal of immunology.

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.

K. Gish, T. Uziel, D. Chao, 2018, Cancer research.

The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.

H. Ochs, A. Aruffo, D. Hollenbaugh, 1994, Research in immunology.

Expression of functional CD40 by vascular endothelial cells

P. Kiener, J. Simon, A. Aruffo, 1995, The Journal of experimental medicine.

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

W. Liu, Z. Dezső, L. Bigelow, 2022, Nature Cancer.

Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase.

D. Cheney, Henry H. Gu, E. Iwanowicz, 2002, Bioorganic & medicinal chemistry letters.

Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis.

J Bajorath, J. Bajorath, A. Aruffo, 1995, Biochemistry.

Identification of hyaluronic acid binding sites in the extracellular domain of CD44

I. Stamenkovic, R. Peach, A. Aruffo, 1993, Journal of Cell Biology.

CD62/P-selectin binding sites for myeloid cells and sulfatides are overlapping.

J. Bajorath, A. Aruffo, W. Harte, 1994, Biochemistry.

Interaction of P-selectin (CD62) and its cellular ligand: analysis of critical residues.

J. Bajorath, A. Aruffo, D. Hollenbaugh, 1993, Biochemistry.

Effects of chemical modification on the binding activities of P-selectin mutants.

A. Aruffo, D. Hollenbaugh, P. Senter, 1995, Biochemistry.

Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice

D. Hollenbaugh, F. Harding, J. Samayoa, 2017, The Journal of Immunology.

3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships.

Ping Chen, Derek J. Norris, Henry H. Gu, 2003, Bioorganic & medicinal chemistry letters.

The TosMIC approach to 3-(oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors.

E. Iwanowicz, J. Barrish, D. Hollenbaugh, 2002, Bioorganic & medicinal chemistry letters.

A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase.

Henry H. Gu, E. Iwanowicz, J. Barrish, 2002, Bioorganic & medicinal chemistry letters.

Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.

D. Cheney, Henry H. Gu, E. Iwanowicz, 2002, Journal of medicinal chemistry.

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

K. Gish, G. Demetri, Ying Huang, 2018, Experimental and Molecular Therapeutics.

Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction.

J Bajorath, J. Bajorath, H. Ochs, 1995, Biochemistry.

BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions.

J. Bajorath, P. Stanley, A. Aruffo, 1997, The Journal of pharmacology and experimental therapeutics.

Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

D. Hollenbaugh, R. Sorensen, L. Leiva, 1998, Journal of clinical immunology.

The molecular basis of X-linked agammaglobulinemia, hyper-IgM syndrome, and severe combined immunodeficiency in humans.

H. Ochs, A. Aruffo, D. Hollenbaugh, 1994, Current opinion in hematology.

Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996.

P. Linsley, A. Aruffo, C. Larsen, 2011, Journal of immunology.

Expression of functional CD40 by vascular endothelial cells

P. Kiener, A. Aruffo, R. Denfeld, 1995, The Journal of experimental medicine.

Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation

Z. Milas, C. Larsen, Shivaprakash Gangappa, 2009, The Journal of Immunology.

Expression of Functional Cd40 by Vascular Endothelial Cells

R. Denfeld, D. Hollenbaugh, N. Mischel-Petty, 1995 .

Identification of hyaluronic acid binding sites in the extracellular domain of CD44

I. Stamenkovic, A. Aruffo, D. Hollenbaugh, 1993, The Journal of cell biology.

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.

K. Gish, T. Uziel, D. Chao, 2018, Cancer research.

Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.

A. Gown, P. Linsley, M. Kay, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Development of an immunoassay for BMS-191352, a single-chain immunotoxin, and its application to toxicokinetic studies.

D. Hollenbaugh, S. Kaul, B. Damle, 1998, Journal of immunoassay.